Niaspan and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Niaspan (niacin), especially for people who are male, 60+ old, also take Temazepam, and have High density lipoprotein decreased.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Niaspan. It is created by eHealthMe based on reports of 44,502 people who have side effects when taking Niaspan from the FDA, and is updated regularly.

What is Niaspan?

Niaspan has active ingredients of niacin. It is often used in high blood cholesterol. eHealthMe is studying from 45,453 Niaspan users. Check the latest studies of Niaspan.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,499 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 19, 2026

44,502 people reported to have side effects when taking Niaspan.
Among them, 22 people (0.05%) have Interstitial lung disease.

Could Niaspan cause Interstitial lung disease?

Among these 22 people:

What is the gender of people who have Interstitial lung disease when taking Niaspan? *

female: 22.73 %
male: 77.27 %

What is the age of people who have Interstitial lung disease when taking Niaspan? *

What are other drugs people take besides Niaspan? *

What are other side effects people have besides Interstitial lung disease? *

Bradycardia (abnormally slow heart action): 12 people, 54.55%
Hypotension (abnormally low blood pressure): 12 people, 54.55%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 11 people, 50.00%
Injury: 11 people, 50.00%
Nausea (feeling of having an urge to vomit): 11 people, 50.00%
Dyspnea (difficult or laboured breathing): 11 people, 50.00%
Dizziness: 11 people, 50.00%
Urination - Excessive At Night: 10 people, 45.45%
Cardiac Disorder: 10 people, 45.45%
Nausea And Vomiting: 10 people, 45.45%

What are the existing conditions these people have? *

High Density Lipoprotein Decreased: 2 people, 9.09%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 4.55%
Gout (uric acid crystals building up in the body): 1 person, 4.55%
Anaemia (lack of blood): 1 person, 4.55%
Atherosclerosis (disorder of the arteries): 1 person, 4.55%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 4.55%
Belching (release of gas from the digestive tract): 1 person, 4.55%
Bone Marrow Failure: 1 person, 4.55%
Cardiac Disorder: 1 person, 4.55%
Diabetes: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Niaspan and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Niaspan:

Niaspan (45,453 reports)

Browse all side effects of Niaspan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,499 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Loebl T, Raskin S, "A novel case report: acute manic psychotic episode after treatment with niacin", The Journal of neuropsychiatry and clinical neurosciences, 2013 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Loebl T, Raskin S, "A novel case report: acute manic psychotic episode after treatment with niacin", The Journal of neuropsychiatry and clinical neurosciences, 2013 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on niacin (the active ingredients of Niaspan) and Niaspan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.